Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 110,331

Document Document Title
WO/2015/136247A1
The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called "DREADD" receptor being characterised by (i) a decreased respons...  
WO/2015/136253A1
The disclosure provides extended release pharmaceutical formulations comprising an opioid,particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The ...  
WO/2015/136003A3
Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition is used for the treatment of Parkinson's disease, restl...  
WO/2015/137441A1
Provided is an anti-myristoylated protein antibody or antigen-binding fragment thereof, characterized by having a light-chain variable domain consisting of CDR-L1 comprising the amino acid sequence shown by Sequence No. 1, CDR-L2 compris...  
WO/2015/136515A1
Compositions, methods and devices for administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods can be utilized for treating conditions such as neuropsychiatric sympto...  
WO/2015/136541A3
A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the a...  
WO/2015/138689A1
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegen...  
WO/2015/137887A1
The present invention relates to fused pyrimidine-based hydroxamate compounds of formula (I), comprising a hydroxamate group, that are inhibitors of histone deacetylase (HDAC) and kinases. More particularly, the present invention relates...  
WO/2015/138496A1
Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazin...  
WO/2015/138208A1
The present invention provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof.  
WO/2015/136255A1
The invention relates to the use of agents for the inhibition of caspase-2 and caspase-6 in the protection of central and peripheral neurons. In particular, the invention comprises an inhibitor of caspase-2 for use in the treatment of a ...  
WO/2015/136463A1
The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the inven...  
WO/2015/137499A2
 A hydrogen molecule-supplying exterior body (1) for producing a hydrogen-containing biological application solution, said hydrogen molecule-supplying exterior body (1) being provided with a water vapor-permeable container (12) in whic...  
WO/2015/136543A1
Compositions, methods and devices for administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods can be utilized for treating conditions such as neuropsychiatric sympto...  
WO/2015/137357A1
 The present invention provides a composition containing a sophorolipid, physiologically active substance and oil and fat, said composition being capable of improving the bioavailability of the physiologically active substance when ora...  
WO/2015/135474A1
Disclosed are a pentacyclic triterpene compound represented by general formula (I) and pharmaceutical compositions containing the compound. Also disclosed is use of the compound in preparation of a PS1/BACE1 interaction inhibitor, and us...  
WO/2015/136947A1
The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in th...  
WO/2015/136090A1
The present invention relates to tricyclic hexahydrodiazepinoquino lines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially ago...  
WO/2015/132800A1
The present invention relates to a composition for relieving one or more of the conditions of pain, stress and insomnia comprising Brassica compestris, Bees wax and Dryobalanops camphora. The present invention also provides a formulation...  
WO/2015/132141A1
The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre...  
WO/2015/131856A1
Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation...  
WO/2015/132608A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein R1 and R2 arc as defined in the specification, for use in the prevention or treatment of an ataxic disorder.  
WO/2015/134545A2  
WO/2015/133627A1
 The present invention provides an agent to prevent or improve debility, the agent containing as an active ingredient isoleucine and threonine, and an agent to prevent or improve debility, the agent further containing as an active ingr...  
WO/2015/133329A1
 Provided is a patch preparation having improved adhesion to an adherend so as to be able to continuously administer a drug, particularly a drug having systemic action, in a consistent fashion for an extended period. The patch preparat...  
WO/2015/131788A1
Provided are methods of producing a neuronal phenotype in a glial cell or somatic non-neuronal cell. The methods comprise contacting the glial cell or the somatic non-neuronal cell with a composition including small molecules. Also provi...  
WO/2015/131797A1
Provided are a method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same. Using a combination of a histone deacetylase (HDAC) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, an...  
WO/2015/132800A4
The present invention relates to a composition for relieving one or more of the conditions of pain, stress and insomnia comprising Brassica compestris, Bees wax and Dryobalanops camphora. The present invention also provides a formulation...  
WO/2015/134133A1
The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting loc...  
WO/2015/133771A1
The present invention relates to a novel biomarker for neuroglioma and a use thereof, and more specifically, to a composition for diagnosing neuroglioma comprising a nucleic acid molecule encoding a stanniocalcin protein, a complementary...  
WO/2015/131814A3
The present invention discloses use of a compound represented by formula I, or pharmaceutically acceptable salts thereof in the manufacture of medicaments for the treatment of depression. Specifically it relates to the triple inhibition ...  
WO/2015/132427A1
The invention relates to pyridazin-3(2H)-one derivatives of general structure (I), (II) and (III), which are selective inhibitors of MAO-B, and to the use thereof for producing medicaments for treating disorders derived from the hyperact...  
WO/2015/133122A1
The present invention provides: an agent that has an autonomic adjustment effect and a daily rhythm improvement effect; and a scented product. Specifically, the present invention provides an autonomic adjustment agent for sedation and an...  
WO/2015/134405A1
This invention relates generally to methods and compositions related to therapeutic uses of ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.  
WO/2015/131773A1
The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructiv...  
WO/2015/131814A2
The present invention discloses use of a compound represented by formula I, or pharmaceutically acceptable salts thereof in the manufacture of medicaments for the treatment of depression. Specifically it relates to the triple inhibition ...  
WO/2015/130995A1
Phosphodiesterase (PDE) such as phosphodiesterase type V (PDE5) inhibiting compositions comprising a Sceletium extract are disclosed and described. Methods and systems for inhibiting PDE, as well as, dosage forms comprising a Sceletium e...  
WO/2015/129821A1
The present invention provides a compound that has an autotaxin inhibitory effect and is represented by formula (I) (in the formula, R1, R2, R3, R4a, R4b, R5a, and R5b are as defined in the description.), a medicine that uses said compou...  
WO/2015/127556A1
Compositions for eliciting acute defecation in subjects having a spinal cord injury (SCI subject) are described herein. The compositions may generally comprise one or more of a 5-HT (5-hydroxytryptamine, serotonin) receptor agonist, a be...  
WO/2015/129927A1
Provided herein are compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of ERK5, a BET family protein or both. In certain embodiments, the co...  
WO/2015/130947A1
There are provided methods for treating retroviral infection or inhibiting HIV integrase in target cells or in a patient involving administering to said target cells or to a patient in need of treatment an effective amount of at least on...  
WO/2015/130998A1
Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release en...  
WO/2015/129782A1
Provided is a selective EP2 agonist exhibiting excellent safety. A compound represented by general formula (I) (all the symbols in general formula (I) are as indicated in the description), a salt thereof, an N-oxide thereof, solvates of ...  
WO/2015/127558A1
Compositions for eliciting acute micturition (voiding activity) in subjects having a spinal cord injury (SCI subject) are described herein. The compositions may generally comprise one or more of a 5-HT (5-hydroxytryptamine, serotonin) re...  
WO/2015/128697A1
The present invention relates to molecules of formula (I) where R1 = -SO3H, -PO3H, -PO2(OH)2, -OPO2H2, -NHSO3H, -S (N=H)Me, SH, SR o guanidyl; R = C1-4 alkyl, phenyl or 5 or 6 membered aromatic nitrogen heterocycles; n = 1, 2, 3, 4 o 5; ...  
WO/2015/127512A1
The invention relates to a method of treatment and/or prophylaxis of a disease or disorder of the central nervous system comprising administering to a mammal in need thereof an effective amount of a xanthone-rich plant extract, or a comp...  
WO/2015/129860A1
 The present invention provides a therapeutic agent useful in the treatment and/or prevention of conditions, including cancer, caused by enhanced OPN production, the therapeutic agent containing a compound represented by the formula (i...  
WO/2015/128307A1
The present invention relates to compounds of formula I, wherein Y is N or C-R1'; R1' is hydrogen or F; R1 is hydrogen, halogen or lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; or R2 forms together with R4 a 6 member...  
WO/2015/127549A1
The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic...  
WO/2015/130994A1
Phosphodiesterase-4 (PDE4) inhibiting compositions comprising a Sceletium and an activity enhancer are disclosed and described. Methods and systems for inhibiting PDE4, as well as, dosage forms comprising a Sceletium extract and an activ...  

Matches 651 - 700 out of 110,331